Unknown

Dataset Information

Pension and state funds dominating biomedical R&D investment: fiduciary duty and public health.


ABSTRACT:

Background

Who benefits from the commercial biomedical research and development (R&D)? Patients-consumers and investors-shareholders have traditionally been viewed as two distinct groups with conflicting interests: shareholders seek maximum profits, patients - maximum clinical benefit. However, what happens when patients are the shareholders? With billions of dollars of public risk capital channeled into the drug development industry, analysing the complex financial architecture and the market for corporate control is essential for understanding industry's characteristics, such as pricing strategies or R&D priorities.

Results

Adding investments by governmentally-mandated retirement schemes, central and promotional banks, and sovereign wealth funds to tax-derived governmental

SUBMITTER: Roller S 

PROVIDER: S-EPMC6833262 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature